IRON DISC MEDICINE INC

Disc Medicine to Participate in Upcoming Investor Conferences

Disc Medicine to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at four upcoming investor conferences:

  • Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 3rd at 10:55 a.m. ET.
  • 2025 Wells Fargo Healthcare Conference on Thursday, September 4th at 4:30 p.m. ET.
  • H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9th at 12:00 p.m. ET.

  • Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10th at 1:05 p.m. ET.

Live webcasts of the fireside chats will be available through the investor relations section of the Company's website at and an archived replay will be available after the event.

About Disc Medicine

Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit .

Media Contact

Peg Rusconi

Deerfield Group

Investor Relations Contact

Christina Tartaglia

Precision AQ



EN
27/08/2025

Underlying

IRONDISC MEDICINE INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DISC MEDICINE INC

 PRESS RELEASE
Free
IRON DISC MEDICINE I...

Disc Medicine Announces Submission of New Drug Application (NDA) to US...

Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP) Disc is seeking accelerated approval and priority review of its NDA submissionFDA decision to accept and file the NDA for review occurs within 60 days of submission WATERTOWN, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematol...

September 30, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 43.04
XNCR XENCOR INC.
SCHL Scholastic Corp... ... (+35)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

XNCR XENCOR INC.
SCHL SCHOLASTIC CORPORATION
MRCY MERCURY SYSTEMS INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
KURA KURA ONCOLOGY INC.
JACK JACK IN THE BOX INC.
INTC INTEL CORPORATION
HELE HELEN OF TROY LIMITED
CROX CROCS INC.
AIR AAR CORP.
UNFI UNITED NATURAL FOODS INC.
LINK INTERLINK ELECTRONICS
SRRK SCHOLAR ROCK HOLDING CORPORATION
STOK STOKE THERAPEUTICS
IMTX IMMATICS N V (A)
KYMR KYMERA THERAPEUTICS
LRMR LARIMAR THERAPEUTICS INC
COGT COGENT BIOSCIENCES INC
RLAY RELAY THERAPEUTICS
HIMS HIMS AND HERS HEALTH INC (A)
VERA VERA THERAPEUTICS INC
TNGX TANGO THERAPEUTICS INC
DSGN DESIGN THERAPEUTICS INC
GLUE MONTE ROSA THERAPEUTICS INC
MBC_w MASTERBRAND INC
IRON DISC MEDICINE INC
CTNM CONTINEUM THERAPEUTICS INC
PACS PACS GROUP INC
ZBIO ZENAS BIOPHARMA INC.
UPB UPSTREAM BIO INC
MIR MIRION TECHNOLOGIES INC
SION SIONNA THERAPEUTICS INC
KLRS KALARIS THERAPEUTICS INC
BKTI BK TECHNOLOGIES CORP
EMPG EMPRO GROUP INC
09/29/25 September 29, 2025 1 EN
 PRESS RELEASE
Free
IRON DISC MEDICINE I...

Disc Medicine to Participate in Upcoming Investor Conferences

Disc Medicine to Participate in Upcoming Investor Conferences WATERTOWN, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at four upcoming investor conferences: Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 3rd at 10:55 a.m. ET. 2025 Wells Fargo Healthcare Conference on Thursday, Sep...

August 27, 2025 1 EN
 PRESS RELEASE
Free
IRON DISC MEDICINE I...

Disc Medicine Reports Second Quarter 2025 Financial Results and Provid...

Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update Company on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) under accelerated approval pathway in October 2025, supported by successful pre-NDA meetingExpect initial data from Phase 2 study of DISC-0974 in patients with anemia of myelofibrosis (MF) and multiple dose data from Phase 1b study of DISC-0974 in patients with anemia of non-dialysis-dependent chronic kidney disease (NDD-CKD) in Q4 2025Initiated Phase 2 study of DISC-3405 in polycythemia vera (PV) with initial data expe...

August 7, 2025 1 EN
 PRESS RELEASE
Free
IRON DISC MEDICINE I...

Disc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to...

Disc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in October 2025 WATERTOWN, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced positive feedback from its pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) to discuss the planned NDA submission for b...

July 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch